FDA

The colorant was banned from cosmetics and non-oral medications years ago because a study showed it caused cancer in rats. But it remained approved for many snack foods and other products until this week.

Some Trump insiders are ready to take on the food industry. It remains to be seen whether their entree will result in any meaningful change in government oversight of “Big Food” — or in American health.

The most popular nasal decongestant on U.S. pharmacy shelves may not be there much longer. The FDA recently announced plans to phase out phenylephrine.

Johns Hopkins surgeon Dr. Marty Makary is his choice for the FDA and Dr. Janette Nesheiwat is in line to be the next surgeon general. Dr. Dave Weldon of Florida is slated to run the CDC.

The state sued the FDA over what it said was a “reckless delay” in approving its drug importation plan. Nearly a year after the federal officials gave the green light, the program has yet to begin.

The guidelines took years to finalize, but while regulators were drafting them, a new trend emerged: online pharmaceutical influencers with little government oversight.

Experts who track food safety say improvements are needed, but the situation is not getting worse. Federal officials say the U.S. food supply “remains one of the safest in the world.”

The FDA considers plants that have gone more than five years without an inspection to be a significant risk. Officials say the work has been hampered by difficulties recruiting and retaining inspectors.

USF allergist Dr. Thomas Casale told an FDA advisory panel last year. that of the 6 million prescriptions written for EpiPen auto-injectors each year, more than 40% are never filled.

The story of MitraClip, a device Dr. Oz helped invent to treat faulty heart valves, is a cautionary tale about the science, business and regulation of medical technology.

The questionable imaging tests by North Shore Medical Center were done between March 2022 and March 2024. The facility is owned by Steward Health Care, which is undergoing Chapter 11 bankruptcy.

Advisers ultimately said sticking with JN.1 rather than its offshoots promises to offer a better chance at cross-protection. The FDA will decide the final recipe soon.